If these kinases were activated early in AD evolution and correlated with other biomarkers such as Aβ1-42, tau, and phosphorylated tau and cognitive decline, this could be a major incentive to envisage the use of early combination therapy with kinase inhibitors in AD patients. Here, MAPT is linked to Alzheimer disease.